{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:18:34Z","timestamp":1781817514054,"version":"3.54.5"},"reference-count":38,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The serious nature of post-vaccination anaphylaxis requires healthcare professionals to be adequately trained to respond to these hypersensitivity emergencies. The aim of this study was to compare outcomes reported with cases of vaccine anaphylaxis stratified by administration setting. We queried reports in the Vaccine Adverse Event Reporting System (VAERS) database from 2017 to 2022 and identified cases involving anaphylaxis with an onset within one day of vaccine administration. The primary outcome was the combined prevalence of death or disability for each setting while the secondary outcome was the prevalence of hospitalization. Adjusted (age, sex, prior history of allergy, vaccine type) odds ratios (aOR) and associated 95% confidence intervals (CI) were calculated using logistic regression analysis. A total of 2041 cases of anaphylaxis comprised the primary study cohort with representation in the sample from all 50 US states and the District of Columbia. The mean age was 43.3 \u00b1 17.5 years, and most cases involved women (79.9%). Cases of anaphylaxis were reported after receiving a coronavirus vaccine (85.2%), influenza vaccine (5.9%), tetanus vaccine (2.2%), zoster vaccine (1.6%), measles vaccine (0.7%), and other vaccine (4.5%). Outcomes associated with reports of vaccine anaphylaxis included 35 cases of death and disability and 219 hospitalizations. Compared with all other settings, the aOR of death and disability when anaphylaxis occurred was 1.92 (95% CI, 0.86\u20134.54) in a medical provider\u2019s office, 0.85 (95% CI, 0.26\u20132.43) in a pharmacy and 1.01 (95% CI, 0.15\u20133.94) in a public health clinic. Compared with all other settings, the aOR of hospitalization when anaphylaxis occurred was 1.02 (95% CI, 0.71\u20131.47) in a medical provider\u2019s office, 1.06 (95% CI, 0.72\u20131.54) in a pharmacy, and 1.12 (95% CI, 0.61\u20131.93) in a public health clinic. An analysis of a national database across six years revealed no significant differences in the odds of death\/disability and odds of hospitalization associated with post-vaccination anaphylaxis in the medical office, pharmacy, and public health clinic compared with all other settings. This study expands our understanding of the safety of immunization services and reinforces that all settings must be prepared to respond to such an emergency.<\/jats:p>","DOI":"10.3390\/vaccines11020276","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T05:57:23Z","timestamp":1675058243000},"page":"276","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Death and Disability Reported with Cases of Vaccine Anaphylaxis Stratified by Administration Setting: An Analysis of the Vaccine Adverse Event Reporting System from 2017 to 2022"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-1899","authenticated-orcid":false,"given":"Rachel C.","family":"Klosko","sequence":"first","affiliation":[{"name":"School of Pharmacy & Pharmaceutical Sciences, Binghamton University, Johnson City, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Lynch","sequence":"additional","affiliation":[{"name":"School of Pharmacy & Pharmaceutical Sciences, Binghamton University, Johnson City, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle L.","family":"Cabral","sequence":"additional","affiliation":[{"name":"School of Pharmacy & Pharmaceutical Sciences, Binghamton University, Johnson City, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanneboyina","family":"Nagaraju","sequence":"additional","affiliation":[{"name":"School of Pharmacy & Pharmaceutical Sciences, Binghamton University, Johnson City, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne A.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Master of Public Health Program, Decker College of Nursing and Health Sciences, Binghamton University, Johnson City, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Steinberg","sequence":"additional","affiliation":[{"name":"United Health Services Family Medicine Residency and Upstate Medical University College of Medicine Clinical Campus, Johnson City, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth L.","family":"McCall","sequence":"additional","affiliation":[{"name":"School of Pharmacy & Pharmaceutical Sciences, Binghamton University, Johnson City, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/all.14840","article-title":"Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives","volume":"76","author":"Sampath","year":"2021","journal-title":"Allergy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2471\/BLT.07.040089","article-title":"Vaccination greatly reduces disease, disability, death and inequity worldwide","volume":"86","author":"Andre","year":"2008","journal-title":"Bull. World Health Organ."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.15585\/mmwr.mm7037e1","article-title":"Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths by Vaccination Status\u201313 U.S.; Jurisdictions, April 4\u2013July 17, 2021","volume":"70","author":"Scobie","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity","volume":"141","author":"McNeil","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"CDC COVID-19 Response Team, and Food and Drug Administration (2021). Allergic Reactions Including Anaphylaxis after Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine-United States, December 14\u201323, 2020. MMWR Morb. Mortal. Wkly. Rep., 70, 46\u201351.","DOI":"10.15585\/mmwr.mm7002e1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for Adverse Events after COVID-19 mRNA Vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.vaccine.2021.11.066","article-title":"Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines","volume":"40","author":"Maltezou","year":"2022","journal-title":"Vaccine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4168\/aair.2021.13.4.526","article-title":"COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria\/Angioedema\/Anaphylaxis Working Group","volume":"13","author":"Kim","year":"2021","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis","volume":"145","author":"Shaker","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_10","unstructured":"Centers for Disease Control and Prevention (2022, October 16). Vaccines and Immunizations. Preparing for the Potential Management of Anaphylaxis, Available online: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/managing-anaphylaxis.html."},{"key":"ref_11","unstructured":"Office of the Assistant Secretary of Health (2022, October 16). Guidance for PREP Act Coverage for Qualified Pharmacy Technicians and State-Authorized Pharmacy Interns for Childhood Vaccines, COVID-19 Vaccines, and COVID-19 Testing. HHS, Available online: https:\/\/www.hhs.gov\/sites\/default\/files\/prep-act-guidance.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1016\/j.vaccine.2016.08.085","article-title":"Impact of pharmacists as immunizers on vaccination rates: A systematic review and meta-analysis","volume":"34","author":"Isenor","year":"2016","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.japh.2022.06.008","article-title":"The impact of pharmacist involvement on immunization uptake and other outcomes: An updated systematic review and meta-analysis","volume":"62","author":"Le","year":"2022","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Eid, D., Osborne, J., and Borowicz, B. (2019). Moving the Needle: A 50-State and District of Columbia Landscape Review of Laws Regarding Pharmacy Technician Vaccine Administration. Pharmacy, 7.","DOI":"10.3390\/pharmacy7040168"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.24926\/iip.v5i2.336","article-title":"Assessing Pharmacists\u2019 Attitudes and Barriers Involved with Immunizations","volume":"5","author":"Aldrich","year":"2014","journal-title":"Innov Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1016\/j.vaccine.2018.07.027","article-title":"National survey of pharmacy-based immunization services","volume":"36","author":"Westrick","year":"2018","journal-title":"Vaccine"},{"key":"ref_17","unstructured":"U.S. Department of Health and Human Services (2022, October 16). Vaccine Adverse Event Reporting System (VAERS), Available online: https:\/\/vaers.hhs.gov\/about.html."},{"key":"ref_18","unstructured":"(2022, October 16). Medical Dictionary for Regulatory Activities. Available online: https:\/\/www.meddra.org\/."},{"key":"ref_19","unstructured":"American College of Allergy, Asthma and Immunology (2022, October 16). Anaphylaxis: Causes, Symptoms and Treatment. Available online: https:\/\/acaai.org\/allergies\/symptoms\/anaphylaxis\/."},{"key":"ref_20","unstructured":"(2022, November 11). GraphPad Prism, Available online: www.graphpad.com."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40259-022-00536-8","article-title":"Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management","volume":"36","author":"Luxi","year":"2022","journal-title":"BioDrugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13223-021-00613-7","article-title":"Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: A systematic review and meta-analysis","volume":"17","author":"Alhumaid","year":"2021","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100517","DOI":"10.1016\/j.waojou.2021.100517","article-title":"COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee","volume":"14","author":"Turner","year":"2021","journal-title":"World Allergy Organ. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1001\/jama.2021.0600","article-title":"Allergic Reactions Including Anaphylaxis after Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.jaci.2021.04.002","article-title":"Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines","volume":"147","author":"Risma","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1081-1206(10)61367-1","article-title":"Anaphylaxis: A review of 601 cases","volume":"97","author":"Webb","year":"2006","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaci.2007.10.012","article-title":"Analysis of food-allergic and anaphylactic events in the National Electronic Injury Surveillance System","volume":"121","author":"Ross","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jaci.2007.07.040","article-title":"Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993\u20131994 to 2004\u20132005","volume":"120","author":"Poulos","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaci.2014.11.003","article-title":"Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production","volume":"135","author":"Hox","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/ACI.0000000000000568","article-title":"Gender differences in anaphylaxis","volume":"19","author":"Salvati","year":"2019","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.anai.2011.01.014","article-title":"Analysis of anaphylaxis cases after vaccination: 10-year review from the National Vaccine Injury Compensation Program","volume":"106","author":"Josephs","year":"2011","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7458","DOI":"10.1016\/j.vaccine.2020.09.072","article-title":"The reporting sensitivity of the Vaccine Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barr\u00e9 syndrome","volume":"38","author":"Miller","year":"2020","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.drudis.2020.11.025","article-title":"Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic","volume":"26","author":"Rizk","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.japh.2022.08.010","article-title":"Essential services: Quantifying the contributions of America\u2019s pharmacists in COVID-19 clinical interventions","volume":"62","author":"Grabenstein","year":"2022","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_35","unstructured":"Centers for Disease Control and Prevention (2022, December 19). Influenza (Flu). Influenza Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults, United States, Available online: https:\/\/www.cdc.gov\/flu\/fluvaxview\/dashboard\/vaccination-administered.html."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s11096-021-01301-7","article-title":"Pharmacists\u2019 involvement in COVID-19 vaccination across Europe: A situational analysis of current practice and policy","volume":"43","author":"Paudyal","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1542\/peds.112.4.815","article-title":"Risk of anaphylaxis after vaccination of children and adolescents","volume":"112","author":"Bohlke","year":"2003","journal-title":"Pediatrics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/pds.1323","article-title":"Data mining for signals in spontaneous reporting databases: Proceed with caution","volume":"16","author":"Stephenson","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/2\/276\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:17:32Z","timestamp":1760120252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/2\/276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["vaccines11020276"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11020276","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,28]]}}}